To assess changes in the rates and numbers of newly identified cancer diagnoses before and during the COVID-19 pandemic in the United States.
Comparative analysis tracking newly identified cancer diagnoses across baseline and COVID-19 pandemic periods.
Significant reductions occurred in newly identified cancer cases during the COVID-19 period compared to baseline across various tumor types, including pancreatic cancer.
Abstract
19 period and the number of women with pancreatic cancer in the baseline and COVID-19 periods,